Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in osteoarthritis.

Christopher W Wu1, Kenneth C Kalunian

  • 1Center of Innovative Therapies at the University of San Diego at California, 9320 Campus Point Drive, Suite 225, La Jolla, CA 92037-0943, USA.

Clinics in Geriatric Medicine
|May 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Anifrolumab Treatment Normalizes Hematologic Parameters and Several Serologic Markers in Patients With Systemic Lupus Erythematosus.

ACR open rheumatology·2026
Same author

Deep profiling of lupus nephritis kidneys reveals dynamic changes in myeloid cells associated with disease progression.

Annals of the rheumatic diseases·2026
Same author

A population-scale atlas of blood and tissue in lupus nephritis.

bioRxiv : the preprint server for biology·2026
Same author

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

High interferon response signatures in SLE patient leukocytes are associated with increased transposable element expression in gene introns and intergenic regions.

Mobile DNA·2025
Same journal

Cardiovascular Prevention in Older Adults: From Estimation to Treatment.

Clinics in geriatric medicine·2026
Same journal

Preventive Cardiology for the Clinically Complex Older Adult.

Clinics in geriatric medicine·2026
Same journal

A Preventive Neurology Perspective on Promoting Brain Health and Preventing Cardiovascular Disease.

Clinics in geriatric medicine·2026
Same journal

Secondary Prevention in Older Adults: Putting It All Together.

Clinics in geriatric medicine·2026
Same journal

Primary Prevention in Older Adults: Putting It All Together.

Clinics in geriatric medicine·2026
Same journal

Managing Bleeding Risk in Older Adults: Antithrombotics and Anticoagulants.

Clinics in geriatric medicine·2026
See all related articles

Osteoarthritis (OA) management currently focuses on symptom relief, not halting disease progression. Developing disease-modifying osteoarthritis drugs (DMOADs) is crucial for future patient outcomes.

Area of Science:

  • Rheumatology
  • Orthopedics
  • Biomedical Engineering

Background:

  • Osteoarthritis (OA) poses a significant societal burden, comparable to ischemic heart disease.
  • Aging populations and rising obesity rates are expected to exacerbate OA's impact.
  • Current OA treatments primarily alleviate pain and improve function, without affecting disease incidence or progression.

Purpose of the Study:

  • To highlight the critical need for developing disease-modifying osteoarthritis drugs (DMOADs).
  • To explore recent advances in understanding OA pathophysiology.
  • To identify potential therapeutic targets for OA treatment.

Main Methods:

  • Review of current OA pathophysiology research.
  • Analysis of factors influencing OA progression.

Related Experiment Videos

  • Examination of the role of inflammation and chondrocyte function.

    • Main Results:

    • Advances in understanding OA offer optimism for disease modification.
    • Phenotype-based treatment strategies are emerging.
    • Identifying initiating events in cartilage destruction is key.

    Conclusions:

    • Developing DMOADs is a paramount research challenge.
    • Further research into cartilage destruction, pathologic influences, and chondrocyte homeostasis is necessary.
    • Targeting specific pathways holds promise for future OA therapies.